{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:51:17Z","timestamp":1791579077004,"version":"4.3.4"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["HORIZON-MISS-CANCER-2022-01"],"award-info":[{"award-number":["HORIZON-MISS-CANCER-2022-01"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101104574"],"award-info":[{"award-number":["101104574"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejca.2026.117762","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:49:24Z","timestamp":1790981364000},"page":"117762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Towards a more proportionate EU framework for low-intervention clinical trials: Lessons from the UK and Switzerland"],"prefix":"10.1016","volume":"248","author":[{"given":"Rana","family":"Kassas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Kromar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117762_bib1","unstructured":"European Commission. Proposal for a Regulation of the European Parliament and of the Council laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulation (EC) No 1394\/2007 and Regulation (EU) No 536\/2014 and repealing Regulation (EC) No 726\/2004, Regulation (EC) No 141\/2000 and Regulation (EC) No 1901\/2006, COM(2023) 193 final; 2023. Final compromise text: Council of the European Union, document 6366\/26, https:\/\/data.consilium.europa.eu\/doc\/document\/ST-6366-2026-INIT\/en\/pdf; 2026 [accessed 18 September 2026]."},{"key":"10.1016\/j.ejca.2026.117762_bib6","unstructured":"Medicines and Healthcare products Regulatory Agency. Clinical trials for medicines: notifiable trials, https:\/\/www.gov.uk\/guidance\/clinical-trials-for-medicines-notifiable-trials; 2026 [accessed 18 September 2026]."},{"key":"10.1016\/j.ejca.2026.117762_bib8","unstructured":"European Commission. Clinical Trials Regulation (EU) No 536\/2014: questions & answers, version 7.2, https:\/\/health.ec.europa.eu\/document\/download\/bd165522-8acf-433a-9ab1-d7dceae58112_en?filename=regulation5362014_qa_en.pdf; 2026 [accessed 18 September 2026]."},{"key":"10.1016\/j.ejca.2026.117762_bib9","unstructured":"Heads of Medicines Agencies, Clinical Trials Coordination Group. CTCG key documents list: template cover letter for initial applications, version 7, https:\/\/www.hma.eu\/about-hma\/working-groups\/clinical-trials-coordination-group.html; 2026 [accessed 18 September 2026]."},{"key":"10.1016\/j.ejca.2026.117762_bib10","unstructured":"Organisation for Economic Co-operation and Development. Recommendation of the Council on the Governance of Clinical Trials, OECD\/LEGAL\/0397, https:\/\/legalinstruments.oecd.org\/public\/doc\/281\/281.en.pdf; 2012 [accessed 18 September 2026]."},{"issue":"4","key":"10.1016\/j.ejca.2026.117762_bib11","doi-asserted-by":"crossref","first-page":"TPS232","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS232","article-title":"EORTC GUCG 2238 De-escalate: a pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-na\u00efve prostate cancer in the era of new AR pathway inhibitors","volume":"42","author":"Grisay","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117762_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115790","article-title":"Convergence of science, regulations and society in cancer clinical research: a perspective based on the EORTC DE-ESCALATE study","volume":"229","author":"Lacombe","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117762_bib13","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117762_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115076","article-title":"Do regulations and policies undermine the social value of independent academic research?","volume":"213","author":"Lacombe","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117762_bib15","unstructured":"European Organisation for Research and Treatment of Cancer. EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials, https:\/\/www.eortc.org\/blog\/2026\/06\/24\/biotech-act-position-paper\/; 2026 [accessed 3 September 2026]."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926015443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926015443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:15:01Z","timestamp":1791576901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926015443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":10,"alternative-id":["S0959804926015443"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117762","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards a more proportionate EU framework for low-intervention clinical trials: Lessons from the UK and Switzerland","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117762","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117762"}}